JP2015199691A - Wnt発現抑制剤 - Google Patents
Wnt発現抑制剤 Download PDFInfo
- Publication number
- JP2015199691A JP2015199691A JP2014080926A JP2014080926A JP2015199691A JP 2015199691 A JP2015199691 A JP 2015199691A JP 2014080926 A JP2014080926 A JP 2014080926A JP 2014080926 A JP2014080926 A JP 2014080926A JP 2015199691 A JP2015199691 A JP 2015199691A
- Authority
- JP
- Japan
- Prior art keywords
- wnt
- phalaenopsis
- extract
- expression
- catenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013814 Wnt Human genes 0.000 title claims abstract description 69
- 108050003627 Wnt Proteins 0.000 title claims abstract description 69
- 230000014509 gene expression Effects 0.000 title claims abstract description 54
- 239000003112 inhibitor Substances 0.000 title claims abstract description 31
- 239000000284 extract Substances 0.000 claims abstract description 51
- 102000015735 Beta-catenin Human genes 0.000 claims abstract description 35
- 108060000903 Beta-catenin Proteins 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 22
- 230000008099 melanin synthesis Effects 0.000 claims abstract description 21
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 241001505935 Phalaenopsis Species 0.000 claims description 80
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 235000013305 food Nutrition 0.000 abstract description 20
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 201000011510 cancer Diseases 0.000 abstract description 9
- 230000019612 pigmentation Effects 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 241001556747 Phalaenopsis aphrodite Species 0.000 abstract description 3
- 230000007170 pathology Effects 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 23
- 238000009472 formulation Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 16
- -1 vacuum concentration Substances 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 102000052547 Wnt-1 Human genes 0.000 description 13
- 108700020987 Wnt-1 Proteins 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 13
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 239000008213 purified water Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000000469 ethanolic extract Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000002674 ointment Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 208000012641 Pigmentation disease Diseases 0.000 description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 229940058015 1,3-butylene glycol Drugs 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000004156 Wnt signaling pathway Effects 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 4
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 4
- 101150019524 WNT2 gene Proteins 0.000 description 4
- 102000052556 Wnt-2 Human genes 0.000 description 4
- 108700020986 Wnt-2 Proteins 0.000 description 4
- 102000052549 Wnt-3 Human genes 0.000 description 4
- 108700020985 Wnt-3 Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010027145 Melanocytic naevus Diseases 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101100154912 Mus musculus Tyrp1 gene Proteins 0.000 description 3
- 208000007256 Nevus Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 101150087532 mitF gene Proteins 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000016929 Casein Kinase Ialpha Human genes 0.000 description 2
- 108010053889 Casein Kinase Ialpha Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 241000287127 Passeridae Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 240000002408 Phalaenopsis lueddemanniana Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 101150010310 WNT-4 gene Proteins 0.000 description 2
- 101150109862 WNT-5A gene Proteins 0.000 description 2
- 230000031712 Wnt receptor signaling pathway, planar cell polarity pathway Effects 0.000 description 2
- 102000052548 Wnt-4 Human genes 0.000 description 2
- 108700020984 Wnt-4 Proteins 0.000 description 2
- 102000043366 Wnt-5a Human genes 0.000 description 2
- 108700020483 Wnt-5a Proteins 0.000 description 2
- 101100485097 Xenopus laevis wnt11b gene Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229940073665 octyldodecyl myristate Drugs 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 1
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000017678 Ota naevus Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 244000127818 Phalaenopsis amabilis Species 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 102000000479 TCF Transcription Factors Human genes 0.000 description 1
- 108010016283 TCF Transcription Factors Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102000006757 Wnt Receptors Human genes 0.000 description 1
- 108010047118 Wnt Receptors Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- KDKJYYNXYAZPIK-UHFFFAOYSA-J aluminum potassium disulfate hydrate Chemical compound O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O KDKJYYNXYAZPIK-UHFFFAOYSA-J 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000021557 concentrated beverage Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000005087 leaf formation Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 208000004942 nevus of Ota Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010807 real-time PCR kit Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 241000233856 x Doritaenopsis Species 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
(1)胡蝶蘭の抽出物を有効成分として含有するWnt発現抑制剤。
(2)Wntが、Wnt/β−カテニンシグナルに関与するWntである、(1)に記載のWnt発現抑制剤。
(3)胡蝶蘭の抽出物を有効成分として含有するメラニン合成抑制剤。
(4)胡蝶蘭が、胡蝶蘭の幼苗である、(1)〜(3)のいずれかに記載の剤。
(5)(1)〜(4)のいずれかに記載の剤を含む化粧品。
(6)(1)〜(4)のいずれかに記載の剤を含む医薬品または医薬部外品。
(7)皮膚外用製剤である、(6)に記載の医薬品または医薬部外品。
(8)(1)〜(4)のいずれかに記載の剤を含む飲食品。
本発明のWnt発現抑制剤は、胡蝶蘭の抽出物を有効成分として含有する。本発明でいう胡蝶蘭には、ファレノプシス属(Phalaenopsis)の各種、及びそれらと交配可能な近縁種であるドリティス属(Doritis)、ドリティノプシス属(Doritaenopsis)等の原種、その種間雑種あるいは属間雑種等が挙げられ、市販されている株を利用することができる。市販されている胡蝶蘭園芸品種の交配親の代表的品種としては、Phalaenopsis amabilis、Phalaenopsis aphrodite、Phalaenopsis schilleriana、Phalaenopsis lueddemanniana、Phalaenopsis equestris、Phalaenopsis intermedia等が挙げられる。また、ファレノプシス属以外の交配親の代表品種としては、ドリティス・プルケリマ(Doritis pulcherima)等が挙げられる。また、ファレノプシス属とドリティス属の交配種を、ドリティノプシス属と称し交配親として用いている。
胡蝶蘭の抽出物を以下のとおり製造した。製造例1〜6において抽出材料として用いた胡蝶蘭幼苗(フラスコ苗)は、葉の長径が3〜8cmの範囲であって、幼苗分化から花芽形成前のメリクロン苗をいう。
胡蝶蘭のフラスコ苗の葉の乾燥物10gを200mLの50%(V/V)エタノール水溶液に室温で4日間浸漬した。得られた抽出液を濾過した後エバポレーターで濃縮乾固して胡蝶蘭の50%エタノール抽出物を1.6g得た。
胡蝶蘭のフラスコ苗の根の乾燥物10gを200mLの50%(V/V)エタノール水溶液に室温で4日間浸漬した。得られた抽出液を濾過した後エバポレーターで濃縮乾固して胡蝶蘭の50%エタノール抽出物を1.7g得た。
胡蝶蘭のフラスコ苗全草の乾燥物10gを200mLの50%(V/V)エタノール水溶液に室温で4日間浸漬した。得られた抽出液を濾過した後エバポレーターで濃縮乾固して胡蝶蘭の50%エタノール抽出物を1.5g得た。
胡蝶蘭のフラスコ苗全草の乾燥物10gに200mLの水を加え、95〜100℃で2時間抽出した。得られた抽出液を濾過し、そのろ液を濃縮し、凍結乾燥して胡蝶蘭の熱水抽出物を2.3g得た。
胡蝶蘭のフラスコ苗全草の乾燥物10gを200mLの50%(V/V)1,3−BG水溶液に室温で5日間浸漬した。得られた抽出液を濾過して胡蝶蘭の1,3−BG抽出物を190g得た。
胡蝶蘭の成体全草の乾燥物10gを200mLの50%(V/V)エタノール水溶液に室温で4日間浸漬した。得られた抽出液を濾過した後エバポレーターで濃縮乾固して胡蝶蘭の50%エタノール抽出物を1.8g得た。
胡蝶蘭の抽出物の効果の評価実験を次のとおり行った。
20% ウシ胎児血清(FBS、ニチレイバイオ社製)を含有するDulbecco's Modified Eagle's Medium(DMEM、Sigma-Aldrich社製)を用いて培養したヒト扁平上皮がん細胞HSC-1(Wnt1発現細胞、JCRB細胞バンク製)を、2%FBS含有DMEMに懸濁し、8ウェルカルチャースライドに1x103個ずつ播種した。24時間培養後、胡蝶蘭抽出物(製造例1〜6)を最終濃度が0.01%になるように添加した2%FBS含有DMEMに交換し、さらに72時間培養した。細胞をPBS(-)にて2回洗浄し、4%パラホルムアルデヒドを加え、室温で10分間インキュベーションして細胞を固定した。
(1) セルカルチャーインサート内でのHSC-1の単独培養
24ウェルプレートの各ウェルに0.7mLの2%FBS含有DMEMを添加し、ポアサイズ0.4 μmのセルカルチャーインサートをその上からセットした。ヒト扁平上皮がん細胞HSC-1を、2%FBS含有DMEMに懸濁し、セルカルチャーインサートに4x104個ずつ播種した。このとき、対照としてHSC-1を含まない2%FBS含有DMEMを添加したものも用意した。24時間後、培地を胡蝶蘭の抽出物(製造例1〜6)を最終濃度が0.01%になるように添加した2%FBS含有DMEMに交換し、さらに72時間培養した。
Medium254に1%となるようにhuman melanocyte growth supplement(Life Technologies社製)を添加した培地(Medium254+)にて培養した継代数1のヒト正常メラノサイト(NHEM、TOYOBO社製)を、Medium254+に懸濁し、24ウェルプレートに4x104個ずつ播種し、72時間培養した。
(2)で用意したNHEMの培地を除き、新しいMedium254を各ウェルに0.7mLずつ添加した。(1)で用意したセルカルチャーインサート内の培地を除き、NHEMを培養した24ウェルプレートにセットし、新しい2%FBS含有DMEMを各セルカルチャーインサートに0.2mLずつ添加し、NHEMとHSC-1を72時間共培養した。
NHEMとHSC-1の共培養後、セルカルチャーインサートと培地を除き、NHEMをPBS(-)にて2回洗浄した後、Trizol Reagent(Invitrogen社製)によって細胞からRNAを抽出した。2-STEPリアルタイムPCRキット(Applied Biosystems社製)を用いて、抽出したRNAをcDNAに逆転写した後、ABI7300(Applied Biosystems社製)により、下記のプライマーセットを用いてリアルタイムPCR(95℃:15秒間、60℃:30秒間、40cycles)を実施し、メラニン合成関連遺伝子(Mitf、Dct、Tyr、Tyrp1)の発現を確認した。その他の操作は定められた方法に従って実施した。
5'-GCAGTGGTTTGGGCTT-3' (配列番号1)
5'-AATTCTGCACCCGGGAATC-3' (配列番号2)
Dct用プライマーセット:
5'-GGAATGCTTTGGAAGGGTTTG-3' (配列番号3)
5'-AAAGCGTTTGTCCCGTTCAG-3' (配列番号4)
Tyr用プライマーセット:
5'-TGCGGTGGGAACAAGAAATC-3' (配列番号5)
5'-GAAGAATGATGCTGGGCTGAGT-3' (配列番号6)
Tyrp1用プライマーセット:
5'-CGAAACACAGTGGAAGGTTACAGT-3' (配列番号7)
5'-CTCCTCAGCCATTCATCAAAGACT-3' (配列番号8)
18srRNA(内部標準)用プライマーセット:
5'-CCGAGCCGCCTGGATAC-3' (配列番号9)
5'-CAGTTCCGAAAACCAACAAAATAGA-3'(配列番号10)
製造例1〜6で製造した胡蝶蘭の抽出物を配合した製品の処方例を以下に示す。以下の処方例において「胡蝶蘭の抽出物」は、製造例1〜6で製造した胡蝶蘭の抽出物のいずれかを意味する。
処方 配合量(重量%)
1.胡蝶蘭の抽出物 0.1
2.1,3−ブチレングリコール 8.0
3.グリセリン 2.0
4.キサンタンガム 0.02
5.クエン酸 0.01
6.クエン酸ナトリウム 0.1
7.エタノール 5.0
8.パラオキシ安息香酸メチル 0.1
9.ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.1
10.香料 0.1
11.精製水 残量
処方 配合量(重量%)
1.胡蝶蘭の抽出物 0.1
2.スクワラン 5.5
3.オリーブ油 3.0
4.ステアリン酸 2.0
5.ミツロウ 2.0
6.ミリスチン酸オクチルドデシル 3.5
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ベヘニルアルコール 1.5
9.モノステアリン酸グリセリン 2.5
10.香料 0.1
11.パラオキシ安息香酸メチル 0.2
12.パラオキシ安息香酸エチル 0.05
13.1,3−ブチレングリコール 8.5
14.精製水 残量
処方 配合量(重量%)
1.胡蝶蘭の抽出物 0.1
2.スクワラン 5.0
3.オリーブ油 5.0
4.ホホバ油 5.0
5.セタノール 1.5
6.モノステアリン酸グリセリン 2.0
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ポリオキシエチレンソルビタン
モノオレエート(20E.O.) 2.0
9.香料 0.1
10.プロピレングリコール 1.0
11.グリセリン 2.0
12.パラオキシ安息香酸メチル 0.2
13.精製水 残量
処方 配合量(重量%)
1.胡蝶蘭の抽出物 0.1
2.エタノール 5.0
3.パラオキシ安息香酸メチル 0.1
4.ポリオキシエチレン硬化ヒマシ油 0.1
5.香料 適量
6.1,3−ブチレングリコール 5.0
7.グリセリン 5.0
8.キサンタンガム 0.1
9.カルボキシビニルポリマー 0.2
10.水酸化カリウム 0.2
11.精製水 残量
処方 配合量(重量%)
1.胡蝶蘭の抽出物 2.0
2.ポリオキシエチレンセチルエーテル(30E.O.) 2.0
3.モノステアリン酸グリセリン 10.0
4.流動パラフィン 5.0
5.セタノール 6.0
6.パラオキシ安息香酸メチル 0.1
7.プロピレングリコール 10.0
8.精製水 残量
処方 配合量(重量%)
1.胡蝶蘭の抽出物 0.1
2.ポリビニルアルコール 12.0
3.エタノール 5.0
4.1,3−ブチレングリコール 8.0
5.パラオキシ安息香酸メチル 0.2
6.パラオキシエチレン硬化ヒマシ油(20E.O.) 0.5
7.クエン酸 0.1
8.クエン酸ナトリウム 0.3
9.香料 適量
10.精製水 残量
処方 配合量(重量%)
1.胡蝶蘭の抽出物 1.0
2.ステアリン酸 2.4
3.ポリオキシエチレンソルビタンモノステアレート(20E.O.) 1.0
4.ポリオキシエチレンセチルエーテル(20E.O.) 2.0
5.セタノール 1.0
6.液状ラノリン 2.0
7.流動パラフィン 3.0
8.ミリスチン酸イソプロピル 6.5
9.パラオキシ安息香酸ブチル 0.1
10.カルボキシメチルセルロースナトリウム 0.1
11.ベントナイト 0.5
12.プロピレングリコール 4.0
13.トリエタノールアミン 1.1
14.パラオキシ安息香酸メチル 0.2
15.二酸化チタン 8.0
16.タルク 4.0
17.ベンガラ 1.0
18.黄酸化鉄 2.0
19.香料 適量
20.精製水 残量
処方 配合量(重量%)
1.胡蝶蘭の抽出物 5.0
2.乾燥コーンスターチ 25.0
3.カルボキシメチルセルロースカルシウム 20.0
4.微結晶セルロース 40.0
5.ポリビニルピロリドン 7.0
6.タルク 3.0
処方 配合量(重量%)
1.胡蝶蘭の抽出物 0.1
2.ステビア 0.05
3.リンゴ酸 5.0
4.香料 0.1
5.精製水 残量
Claims (8)
- 胡蝶蘭の抽出物を有効成分として含有するWnt発現抑制剤。
- Wntが、Wnt/β−カテニンシグナルに関与するWntである、請求項1に記載のWnt発現抑制剤。
- 胡蝶蘭の抽出物を有効成分として含有するメラニン合成抑制剤。
- 胡蝶蘭が、胡蝶蘭の幼苗である、請求項1〜3のいずれかに記載の剤。
- 請求項1〜4のいずれかに記載の剤を含む化粧品。
- 請求項1〜4のいずれかに記載の剤を含む医薬品または医薬部外品。
- 皮膚外用製剤である、請求項6に記載の医薬品または医薬部外品。
- 請求項1〜4のいずれかに記載の剤を含む飲食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014080926A JP6324792B2 (ja) | 2014-04-10 | 2014-04-10 | Wnt発現抑制剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014080926A JP6324792B2 (ja) | 2014-04-10 | 2014-04-10 | Wnt発現抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015199691A true JP2015199691A (ja) | 2015-11-12 |
JP6324792B2 JP6324792B2 (ja) | 2018-05-16 |
Family
ID=54551328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014080926A Active JP6324792B2 (ja) | 2014-04-10 | 2014-04-10 | Wnt発現抑制剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6324792B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018235344A1 (ja) * | 2017-06-19 | 2018-12-27 | 有限会社椎名洋ラン園 | 抗酸化剤、該抗酸化剤を含有するチロシナーゼ活性阻害剤及び美白剤、並びに、該抗酸化剤及び該美白剤の製造方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0570338A (ja) * | 1991-09-12 | 1993-03-23 | Nonogawa Shoji Kk | 化粧料 |
JP2006524211A (ja) * | 2003-04-24 | 2006-10-26 | コティ ビー.ヴィ. | 色素脱失用化粧品 |
KR20090083082A (ko) * | 2008-01-29 | 2009-08-03 | 주식회사 엘지생활건강 | 난초 발효 추출물을 함유하는 피부 기능 개선 조성물 |
WO2009139231A1 (ja) * | 2008-05-16 | 2009-11-19 | 株式会社ニチレイバイオサイエンス | ラン科植物から得られる抽出物およびその製造方法、ならびにラン科植物から得られる抽出物を含有する皮膚外用剤 |
JP2013067582A (ja) * | 2011-09-22 | 2013-04-18 | Nippon Menaade Keshohin Kk | 色素沈着の予防又は改善剤のスクリーニング法とそのスクリーニング法によって見出された色素沈着の予防又は改善剤 |
JP2014173044A (ja) * | 2013-03-12 | 2014-09-22 | Formosa:Kk | 花入り石鹸 |
-
2014
- 2014-04-10 JP JP2014080926A patent/JP6324792B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0570338A (ja) * | 1991-09-12 | 1993-03-23 | Nonogawa Shoji Kk | 化粧料 |
JP2006524211A (ja) * | 2003-04-24 | 2006-10-26 | コティ ビー.ヴィ. | 色素脱失用化粧品 |
KR20090083082A (ko) * | 2008-01-29 | 2009-08-03 | 주식회사 엘지생활건강 | 난초 발효 추출물을 함유하는 피부 기능 개선 조성물 |
WO2009139231A1 (ja) * | 2008-05-16 | 2009-11-19 | 株式会社ニチレイバイオサイエンス | ラン科植物から得られる抽出物およびその製造方法、ならびにラン科植物から得られる抽出物を含有する皮膚外用剤 |
JP2013067582A (ja) * | 2011-09-22 | 2013-04-18 | Nippon Menaade Keshohin Kk | 色素沈着の予防又は改善剤のスクリーニング法とそのスクリーニング法によって見出された色素沈着の予防又は改善剤 |
JP2014173044A (ja) * | 2013-03-12 | 2014-09-22 | Formosa:Kk | 花入り石鹸 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018235344A1 (ja) * | 2017-06-19 | 2018-12-27 | 有限会社椎名洋ラン園 | 抗酸化剤、該抗酸化剤を含有するチロシナーゼ活性阻害剤及び美白剤、並びに、該抗酸化剤及び該美白剤の製造方法 |
CN110691585A (zh) * | 2017-06-19 | 2020-01-14 | 日本椎名洋兰园 | 抗氧化剂、含有该抗氧化剂的酪氨酸酶活性抑制剂和美白剂、以及该抗氧化剂和该美白剂的制造方法 |
JPWO2018235344A1 (ja) * | 2017-06-19 | 2020-04-16 | 有限会社椎名洋ラン園 | 抗酸化剤、該抗酸化剤を含有するチロシナーゼ活性阻害剤及び美白剤、並びに、該抗酸化剤及び該美白剤の製造方法 |
JP7246643B2 (ja) | 2017-06-19 | 2023-03-28 | 有限会社椎名洋ラン園 | 抗酸化剤、該抗酸化剤を含有するチロシナーゼ活性阻害剤及び美白剤、並びに、該抗酸化剤及び該美白剤の製造方法 |
CN110691585B (zh) * | 2017-06-19 | 2023-08-29 | 日本椎名洋兰园 | 抗氧化剂、含有该抗氧化剂的酪氨酸酶活性抑制剂和美白剂、以及该抗氧化剂和该美白剂的制造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP6324792B2 (ja) | 2018-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012051940A (ja) | ビワ葉抽出物を含有する飲食品及び医薬品 | |
KR102124986B1 (ko) | 익모초 추출물 또는 레오누린을 함유하는 근육 질환 예방 또는 치료용 또는 근 기능 개선용 조성물 | |
JP7219942B2 (ja) | Wnt発現抑制剤 | |
JP5819209B2 (ja) | 幹細胞から褐色脂肪細胞への分化促進剤 | |
US11324706B2 (en) | Composition for inhibiting growth of breast cancer stem cells containing phenylacetaldehyde | |
KR101768626B1 (ko) | 홍화황 추출물을 포함하는 미백용 조성물 | |
JP6324792B2 (ja) | Wnt発現抑制剤 | |
JP2015124188A (ja) | 皮脂合成抑制剤 | |
KR102122614B1 (ko) | 테트라셀미스 테트라셀레의 추출물을 유효 성분으로 함유하는 두피 개선 및 탈모 방지용 조성물 | |
JP6034107B2 (ja) | 幹細胞から褐色脂肪細胞への分化促進剤 | |
TW201932128A (zh) | mTOR抑制劑 | |
JP6975964B2 (ja) | Dnaメチル化調節剤 | |
JP2015124189A (ja) | 皮脂合成抑制剤 | |
JP7152737B2 (ja) | Wnt発現抑制剤 | |
KR101579820B1 (ko) | 퀘시아 운둘라타의 추출물 또는 이의 분획물을 유효성분으로 함유하는 암 또는 암 전이 억제용 약학적 조성물 | |
KR101579500B1 (ko) | 율무뿌리 추출물을 포함하는 미백용 조성물 | |
JP7071727B2 (ja) | Dnaメチル化調節剤 | |
JP2011032177A (ja) | Kit切断抑制剤 | |
JP6341661B2 (ja) | 皮脂合成促進剤 | |
JP7161170B2 (ja) | 亜鉛トランスポーター発現促進剤 | |
JP2018193314A (ja) | アポトーシス抑制剤 | |
KR102050650B1 (ko) | 계혈등 추출물을 유효성분으로 포함하는 이동성 피부세포질환 예방 또는 치료용 조성물 | |
KR20230111825A (ko) | 터리풀 추출물을 유효성분으로 포함하는 장질환 예방 또는 치료용 조성물 | |
JP2022186421A (ja) | ベージュ脂肪細胞分化誘導促進剤 | |
KR101718193B1 (ko) | 초록갈파래 추출물을 포함하는 탈모 방지 또는 육모 촉진을 위한 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170306 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180302 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180403 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180411 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6324792 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |